<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:13:13Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8577347" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8577347</identifier>
        <datestamp>2021-11-29</datestamp>
        <setSpec>jvirol</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Virol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Virol</journal-id>
              <journal-id journal-id-type="publisher-id">JVI</journal-id>
              <journal-title-group>
                <journal-title>Journal of Virology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0022-538X</issn>
              <issn pub-type="epub">1098-5514</issn>
              <publisher>
                <publisher-name>American Society for Microbiology</publisher-name>
                <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8577347</article-id>
              <article-id pub-id-type="pmcid">PMC8577347</article-id>
              <article-id pub-id-type="pmc-uid">8577347</article-id>
              <article-id pub-id-type="pmid">34549975</article-id>
              <article-id pub-id-type="pmid">34549975</article-id>
              <article-id pub-id-type="publisher-id">01313-21</article-id>
              <article-id pub-id-type="doi">10.1128/JVI.01313-21</article-id>
              <article-id pub-id-type="publisher-id">jvi.01313-21</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Vaccines and Antiviral Agents</subject>
                </subj-group>
                <subj-group subj-group-type="biological-terms">
                  <compound-subject>
                    <compound-subject-part content-type="code">vaccines</compound-subject-part>
                    <compound-subject-part content-type="label">Vaccines</compound-subject-part>
                  </compound-subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Choi</surname>
                    <given-names>Angela</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Koch</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Kai</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Dixon</surname>
                    <given-names>Groves</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Oestreicher</surname>
                    <given-names>Judy</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Legault</surname>
                    <given-names>Holly</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Stewart-Jones</surname>
                    <given-names>Guillaume B. E.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Colpitts</surname>
                    <given-names>Tonya</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Pajon</surname>
                    <given-names>Rolando</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="no">
                  <name>
                    <surname>Bennett</surname>
                    <given-names>Hamilton</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes" equal-contrib="no">
                  <name>
                    <surname>Carfi</surname>
                    <given-names>Andrea</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <email>Andrea.Carfi@modernatx.com</email>
                </contrib>
                <contrib contrib-type="author" corresp="yes" equal-contrib="no">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2065-2941</contrib-id>
                  <name>
                    <surname>Edwards</surname>
                    <given-names>Darin K.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <email>Darin.Edwards@modernatx.com</email>
                </contrib>
                <aff id="aff1">
                  <label>a</label>
                  <addr-line>Moderna, Inc., Cambridge, Massachusetts, USA</addr-line>
                </aff>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <role>Editor</role>
                  <name>
                    <surname>Gallagher</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <aff>Loyola University Chicago</aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <fn fn-type="equal">
                  <p>Angela Choi, Matthew Koch, and Kai Wu contributed equally to this study. Author order was determined based on the amount of time and effort for conceptualization, data collection, and analysis/interpretation of data.</p>
                </fn>
                <fn fn-type="other">
                  <p><bold>Citation</bold> Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, Stewart-Jones GBE, Colpitts T, Pajon R, Bennett H, Carfi A, Edwards DK. 2021. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. J Virol 95:e01313-21. <ext-link xlink:href="https://doi.org/10.1128/JVI.01313-21" ext-link-type="uri">https://doi.org/10.1128/JVI.01313-21</ext-link>.</p>
                </fn>
              </author-notes>
              <pub-date publication-format="electronic" date-type="preprint">
                <day>22</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date publication-format="electronic" date-type="pub">
                <day>9</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date publication-format="electronic" date-type="collection">
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>9</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>95</volume>
              <issue>23</issue>
              <elocation-id>e01313-21</elocation-id>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2021 Choi et al.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Choi et al.</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="jvi.01313-21.pdf"/>
              <abstract>
                <title>ABSTRACT</title>
                <p>The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization.</p>
                <p><bold>IMPORTANCE</bold> In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.</p>
              </abstract>
              <kwd-group>
                <title>KEYWORDS</title>
                <kwd>COVID-19</kwd>
                <kwd>SARS-CoV-2 variants of concern</kwd>
                <kwd>mRNA-1273</kwd>
                <kwd>neutralization</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group award-type="grant" id="award1">
                  <funding-source id="GS1">
                    <institution-wrap>
                      <institution>Moderna, Inc.</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>Edwards</surname>
                      <given-names>Darin K.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <equation-count count="0"/>
                <ref-count count="12"/>
                <page-count count="5"/>
                <word-count count="2963"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>December 2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>As the coronavirus disease 2019 (COVID-19) pandemic continues to escalate in various parts of the world, several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of interest (VOIs) and variants of concern (VOCs) have emerged, including in the United States (B.1.526, Iota; B.1.427/B.1.429), United Kingdom (B.1.1.7, Alpha), Brazil (P.1, Gamma), India (B.1.617.1, Kappa; B.1.617.2, Delta), South Africa (B.1.351, Beta), Uganda (A.23.1), Nigeria (B.1.525, Eta), Peru (C.37, Lambda), Colombia (B.1.621, Mu), and Angola (A.VOI.V2) (<xref rid="B1" ref-type="bibr">1</xref>). There is growing concern over these variants based on increased transmissibility and the ability of some variants to partially escape both natural and vaccine-induced immunity. Notably, the B.1.617.2 lineage has been classified as a VOC by the World Health Organization due to evidence of an increased rate of transmission, reduced effectiveness of monoclonal antibody treatment, and reduced susceptibility to neutralizing antibodies (<xref rid="B1" ref-type="bibr">1</xref>).</p>
              <p>We previously reported that mRNA-1273, a lipid nanoparticle-encapsulated mRNA-based vaccine encoding the spike glycoprotein of the SARS-CoV-2 Wuhan-Hu-1 isolate, induced high neutralizing-antibody titers in phase 1 trial participants (<xref rid="B2" ref-type="bibr">2</xref>) and was highly effective in preventing symptomatic and severe COVID-19 (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Some VOCs or VOIs, including B.1.351 and P.1, reduced neutralizing-antibody levels in a pseudovirus-based model (<xref rid="B5" ref-type="bibr">5</xref>). Importantly, however, all variants remained susceptible to mRNA-1273 vaccine-elicited serum neutralization (<xref rid="B5" ref-type="bibr">5</xref>). Here, we provide an update on the neutralization activity of vaccine sera against several newly emerged variants, including the Delta variant, B.1.617.2.</p>
            </sec>
            <sec sec-type="results" id="s2">
              <title>RESULTS</title>
              <p>We assessed neutralization activity of sera against D614G pseudovirus (predominant variant in 2020), B.1.1.7, B.1.1.7+E484K, B.1.351-v1, B.1.351-v2, B.1.351-v3, P.1, B.1.617.2-v1, B.1.617.2-v2, B.1.525, B.1.526, B.1.617.1-v1, B.1.617.1-v2, C.37-v1, C.37-v2, B.1.427/B.1.429, B.1.621, A.23.1-v1, A.23.1-v2, and A.VOI.V2 (<xref rid="T1" ref-type="table">Table 1</xref>). Sera from the phase 1 mRNA-1273 clinical trial (8 participants, 1 week following dose 2) were evaluated against each variant (<xref rid="B2" ref-type="bibr">2</xref>). Results showed minimal, statistically nonsignificant effects on neutralization titers against B.1.1.7 and A.23.1-v1 compared to D614G (<italic toggle="yes">P = </italic>0.64 and 0.46, respectively) (<xref rid="F1" ref-type="fig">Fig. 1</xref>). In contrast, all other variants examined showed significantly decreased neutralization titers compared with D614G (<italic toggle="yes">P &lt; </italic>0.01) (<xref rid="F1" ref-type="fig">Fig. 1</xref>), although all remained susceptible to mRNA-1273-elicited serum neutralization. Reductions in neutralization titers for these variants ranged from a factor of 2.1 to 8.4 compared with that for D614G (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). Across the 3 versions of the B.1.351 variant tested, 6.9-fold to 8.4-fold reductions in neutralization were observed compared with that for D614G (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). Among all variants tested, the greatest effect on neutralization was observed for A.VOI.V2 and B.1.351-v3 (8.1-fold and 8.4-fold reductions compared with activity against D614G, respectively). More modest 2.1- to 3.4-fold reductions were measured for P.1, B.1.617.2-v1, B.1.617.2-v2, B.1.526, B.1.617.1-v1, B.1.617.1-v2, C.37-v1, C.37-v2, and A.23.1-v2. Intermediate 4.2- and 5.0-fold reductions were seen for B.1.525 and B.1.621, respectively. mRNA-1273-elicited neutralization titers against B.1.1.7, B.1.1.7+E484K, B.1.427/B.1.429, P.1, and B.1.351-v1 observed herein corroborated previous findings (<xref rid="B5" ref-type="bibr">5</xref>).</p>
              <fig position="float" id="F1">
                <label>FIG 1</label>
                <caption>
                  <p>Neutralization of SARS-CoV-2 pseudoviruses in serum samples. Serum samples were obtained from participants in the mRNA-1273 vaccine phase 1 trial on day 36 (7 days after dose 2). A recombinant vesicular stomatitis virus–based pseudovirus neutralization assay was used to measure neutralization. The pseudoviruses tested incorporated D614G or the spike substitutions present in B.1.1.7 (Alpha), B.1.1.7+E484K (Alpha), B.1.351-v1 (Beta), B.1.351-v2 (Beta), B.1.351-v3 (Beta), P.1 (Gamma), B.1.617.2-v1 (Delta), B.1.617.2-v2 (Delta), B.1.525 (Eta), B.1.526 (Iota), B.1.617.1-v1 (Kappa), B.1.617.1-v2 (Kappa), C.37-v1 (Lambda), C.37-v2 (Lambda), B.1.427/B.1.429, B.1.621 (Mu), A.23.1-v1, A.23.1-v2, and A.VOI.V2 (<xref rid="T1" ref-type="table">Table 1</xref>). The reciprocal neutralizing titers on the pseudovirus neutralization assay at a 50% inhibitory dilution (ID<sub>50</sub>) are shown. In panel A, boxes and horizontal bars denote the interquartile range and the geometric mean titer (GMT), respectively. Whisker end points are equal to the maximum and minimum values below or above the median at 1.5 times the interquartile range (IQR). The GMT fold change over D614G for each variant is shown. In panel B, the colored lines connect the D614G and variant neutralization titers in matched samples. A two-tailed Wilcoxon matched-pairs signed-rank test was performed (**, <italic toggle="yes">P</italic> &lt; 0.01). In both panels, the dots represent results from individual serum samples, and the dotted line represents the lower limit of quantification for titers at 20 ID<sub>50</sub>. Data for B.1.1.7 (Alpha), B.1.1.7+E484K (Alpha), P.1 (Gamma), and B.1.427/B.1.429 were published previously (<xref rid="B5" ref-type="bibr">5</xref>). NAb, neutralizing antibody.</p>
                </caption>
                <graphic xlink:href="jvi.01313-21-f001" position="float"/>
              </fig>
              <table-wrap position="float" id="T1">
                <label>TABLE 1</label>
                <caption>
                  <p>Spike mutations in SARS-CoV-2 variants evaluated in this study</p>
                </caption>
                <alternatives>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col span="1"/>
                      <col span="1"/>
                      <col span="1"/>
                      <col span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Variant name</th>
                        <th rowspan="1" colspan="1">WHO nomenclature</th>
                        <th rowspan="1" colspan="1">Location variant first identified</th>
                        <th rowspan="1" colspan="1">Amino acid change(s) in spike</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">D614G</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Predominant global variant</td>
                        <td rowspan="1" colspan="1">D614G</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.1.7</td>
                        <td rowspan="1" colspan="1">Alpha</td>
                        <td rowspan="1" colspan="1">United Kingdom</td>
                        <td rowspan="1" colspan="1">ΔH69, ΔV70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.1.7+E484K</td>
                        <td rowspan="1" colspan="1">Alpha</td>
                        <td rowspan="1" colspan="1">United Kingdom</td>
                        <td rowspan="1" colspan="1">ΔH69, ΔV70, ΔY144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.351-v1</td>
                        <td rowspan="1" colspan="1">Beta</td>
                        <td rowspan="1" colspan="1">South Africa</td>
                        <td rowspan="1" colspan="1">L18F, D80A, D215G, ΔL242, ΔA243, ΔL244, R246I, K417N, E484K, N501Y, D614G, A701V</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.351-v2</td>
                        <td rowspan="1" colspan="1">Beta</td>
                        <td rowspan="1" colspan="1">South Africa</td>
                        <td rowspan="1" colspan="1">L18F, D80A, D215G, ΔL242, ΔA243, ΔL244, K417N, E484K, N501Y, D614G, A701V</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.351-v3</td>
                        <td rowspan="1" colspan="1">Beta</td>
                        <td rowspan="1" colspan="1">South Africa</td>
                        <td rowspan="1" colspan="1">D80A, D215G, ΔL242, ΔA243, ΔL244, K417N, E484K, N501Y, D614G, A701V</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">P.1</td>
                        <td rowspan="1" colspan="1">Gamma</td>
                        <td rowspan="1" colspan="1">Brazil</td>
                        <td rowspan="1" colspan="1">L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.617.2-v1</td>
                        <td rowspan="1" colspan="1">Delta</td>
                        <td rowspan="1" colspan="1">India</td>
                        <td rowspan="1" colspan="1">T19R, G142D, E156G, ΔF157, ΔR158, L452R, T478K, D614G, P681R, D950N</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.617.2-v2</td>
                        <td rowspan="1" colspan="1">Delta</td>
                        <td rowspan="1" colspan="1">India</td>
                        <td rowspan="1" colspan="1">T19R, T95I, G142D, E156G, ΔF157, ΔR158, L452R, T478K, D614G, P681R, D950N</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.525</td>
                        <td rowspan="1" colspan="1">Eta</td>
                        <td rowspan="1" colspan="1">Nigeria</td>
                        <td rowspan="1" colspan="1">Q52R, A67V, ΔH69, ΔV70, ΔY144, E484K, D614G, Q677H, F888L</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.526</td>
                        <td rowspan="1" colspan="1">Iota</td>
                        <td rowspan="1" colspan="1">United States</td>
                        <td rowspan="1" colspan="1">L5F, T95I, D253G, E484K, D614G, A701V</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.617.1-v1</td>
                        <td rowspan="1" colspan="1">Kappa</td>
                        <td rowspan="1" colspan="1">India</td>
                        <td rowspan="1" colspan="1">T95I, G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.617.1-v2</td>
                        <td rowspan="1" colspan="1">Kappa</td>
                        <td rowspan="1" colspan="1">India</td>
                        <td rowspan="1" colspan="1">G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H, H1101D</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">C.37-v1</td>
                        <td rowspan="1" colspan="1">Lambda</td>
                        <td rowspan="1" colspan="1">Peru</td>
                        <td rowspan="1" colspan="1">G75V, T76I, Δ246-252, D253N, L452Q, F490S, D614G, T859N</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">C.37-v2</td>
                        <td rowspan="1" colspan="1">Lambda</td>
                        <td rowspan="1" colspan="1">Peru</td>
                        <td rowspan="1" colspan="1">T63I, Δ64-76, Δ246-252, D253N, L452Q, E471Q, F490S, D614G, T859N</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.427/B.1.429</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">United States</td>
                        <td rowspan="1" colspan="1">S13I, W152C, L452R, D614G</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">B.1.621</td>
                        <td rowspan="1" colspan="1">Mu</td>
                        <td rowspan="1" colspan="1">Colombia</td>
                        <td rowspan="1" colspan="1">T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, D950N</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">A.23.1-v1</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Uganda</td>
                        <td rowspan="1" colspan="1">F157L, V367F, Q613H, P681R</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">A.23.1-v2</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Uganda</td>
                        <td rowspan="1" colspan="1">R102I, F157L, V367F, E484K, Q613H, P681R</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">A.VOI.V2</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Angola</td>
                        <td rowspan="1" colspan="1">D80Y, ΔY144, ΔI210, D215G, ΔR246, ΔS247, ΔY248, L249M, W258L, R346K, T478R, E484K, H655Y, P681H, Q957H</td>
                      </tr>
                    </tbody>
                  </table>
                  <graphic xlink:href="jvi.01313-21-t001" position="anchor"/>
                </alternatives>
              </table-wrap>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>DISCUSSION</title>
              <p>Among VOCs tested, serum-elicited neutralization of the B.1.1.7 (Alpha) variant was comparable to that of D614G; a range of significantly reduced neutralization titers compared to D614G were observed for other VOCs, including the B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) variants, with reductions ranging from 2.1-fold to 8.4-fold. Results presented here are generally consistent with previous studies examining neutralization activity of mRNA-1273–induced immune sera against VOIs/VOCs (reviewed in reference <xref rid="B6" ref-type="bibr">6</xref>), with similar overall trends using both live-virus and pseudovirus neutralization assays (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Similar trends in neutralizing activity of VOIs/VOCs by sera from individuals immunized with BNT162b2 were also observed (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">–</xref><xref rid="B10" ref-type="bibr">10</xref>). A limitation of this study is that differential variant spike incorporation into the various pseudoviruses might impact neutralization results. Nevertheless, these data emphasize the need to continually assess the ability of mRNA-1273 to confer protection against prevalent and emergent VOIs/VOCs. Such preclinical analyses in conjunction with epidemiological monitoring of the incidence and spread of VOCs directly inform strategies around vaccines targeting SARS-CoV-2 variants. As new variants emerge, including those that lead to greater vaccine breakthrough cases, similar analyses could be designed to test vaccine-induced immunity against variants in either animal or clinical studies. Such data are crucial to inform necessary modifications to COVID-19 mRNA vaccines going forward, which may help to mitigate the ongoing spread of SARS-CoV-2 and the emergence of new variants.</p>
            </sec>
            <sec sec-type="materials|methods" id="s4">
              <title>MATERIALS AND METHODS</title>
              <sec id="s4-1">
                <title>Clinical trial.</title>
                <p>Healthy adult participants (<italic toggle="yes">n</italic> = 8; age [mean ± standard deviation], 34.8 ± 9.7 years; male, 37.5%) were immunized with mRNA-1273 (100 μg) on a prime-boost schedule, and serum was collected 7 days after the booster (day 36). Study protocols and results have been reported previously (<xref rid="B2" ref-type="bibr">2</xref>).</p>
              </sec>
              <sec id="s4-2">
                <title>Recombinant VSV-based pseudovirus assay.</title>
                <p>Codon-optimized full-length spike (S) protein of the original Wuhan-Hu-1 isolate with D614G mutation (D614G) was cloned into a pCAGGS vector. This codon-optimized D614G vector was used as a template for site-directed mutagenesis to incorporate the S variants, listed in <xref rid="T1" ref-type="table">Table 1</xref>. To make SARS-CoV-2 full-length S-pseudotyped recombinant vesicular stomatitis virus ΔG (VSVΔG)-firefly luciferase virus, BHK-21/WI-2 cells (Kerafast) were transfected with the S expression plasmid and subsequently infected with VSVΔG-firefly luciferase as previously described (<xref rid="B11" ref-type="bibr">11</xref>). For the neutralization assay, serially diluted serum samples were mixed with pseudovirus and incubated at 37°C for 45 min. The virus-serum mix was subsequently used to infect A549-hACE2-TMPRSS2 cells (<xref rid="B12" ref-type="bibr">12</xref>) for 18 h at 37°C before addition of ONE-Glo reagent (Promega) for measurement of the luciferase signal by relative luminescence units (RLUs). The percentage of neutralization was calculated based on the RLUs of the virus-only control and subsequently analyzed using the four-parameter logistic curve in Prism v.8 (GraphPad Software, Inc.).</p>
              </sec>
              <sec id="s4-3">
                <title>Statistical analysis.</title>
                <p>A two-sided Wilcoxon matched-pairs signed-rank test was used to compare the same patients against different viruses. Statistical analyses were performed (Prism v.8). Geometric mean titers, lower limit of quantification, and fold change relative to D614G were included.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENTS</title>
              <p>This research was supported by Moderna, Inc., and Biomedical Advanced Research and Development Authority, Department of Health and Human Services (contract 75A50120C00034). This work used samples from the phase 1 mRNA-1273 study (NCT04283461). The mRNA-1273 phase 1 study was sponsored and primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, in part with federal funds from the NIAID under grant awards UM1AI148373 to Kaiser Washington, UM1AI148576, UM1AI148684, and NIH P51 OD011132 to Emory University, and NIH AID AI149644 and contract award HHSN272201500002C to Emmes. Funding for the manufacture of mRNA-1273 phase 1 material was provided by the Coalition for Epidemic Preparedness Innovation.</p>
              <p>A. Choi, M.K., K.W., G.D, J.O., H.L., G.B.E.S.-J., T.C., R.P. H.B., A. Carfi, and D.K.E. are employed by Moderna, Inc., and hold equities from the company.</p>
              <p>We thank Michael Brunner and Michael Whitt for kind support on recombinant VSV-based SARS-CoV-2 pseudovirus production. Medical writing and editorial assistance were provided by Srividya Ramachandran and Jared Cochran of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors.</p>
              <p>Conceptualization: K.W., A. Choi, M.K., J.O., G.B.E.S.-J., H.L., R.P., A. Carfi, and D.K.E.; methodology: K.W., A. Choi, M.K.; formal &amp; statistical analysis: K.W., A. Choi, M.K.; writing—original draft: K.W. and D.K.E.; writing—review and editing: K.W., M.K., A. Choi, G.D., G.B.E.S.-J., T.C., H.B., A. Carfi, and D.K.E. All authors have read and agreed to the published version of the manuscript.</p>
            </ack>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1</label>
                <mixed-citation publication-type="other"><collab>World Health Organization</collab>. <year>2021</year><article-title>Weekly epidemiological update on COVID-19—11 May 2021</article-title>.</mixed-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Rouphael</surname><given-names>NG</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>PC</given-names></string-name>, <string-name><surname>Makhene</surname><given-names>M</given-names></string-name>, <string-name><surname>Coler</surname><given-names>RN</given-names></string-name>, <string-name><surname>McCullough</surname><given-names>MP</given-names></string-name>, <string-name><surname>Chappell</surname><given-names>JD</given-names></string-name>, <string-name><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Pruijssers</surname><given-names>AJ</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>A</given-names></string-name>, <string-name><surname>Flach</surname><given-names>B</given-names></string-name>, <string-name><surname>Doria-Rose</surname><given-names>NA</given-names></string-name>, <string-name><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name><surname>Morabito</surname><given-names>KM</given-names></string-name>, <string-name><surname>O'Dell</surname><given-names>S</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>SD</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>PA</given-names>, <suffix>II</suffix></string-name>, <string-name><surname>Padilla</surname><given-names>M</given-names></string-name>, <string-name><surname>Mascola</surname><given-names>JR</given-names></string-name>, <string-name><surname>Neuzil</surname><given-names>KM</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>H</given-names></string-name>, <string-name><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name><surname>Peters</surname><given-names>E</given-names></string-name>, <string-name><surname>Makowski</surname><given-names>M</given-names></string-name>, <string-name><surname>Albert</surname><given-names>J</given-names></string-name>, <string-name><surname>Cross</surname><given-names>K</given-names></string-name>, <string-name><surname>Buchanan</surname><given-names>W</given-names></string-name>, <string-name><surname>Pikaart-Tautges</surname><given-names>R</given-names></string-name>, <string-name><surname>Ledgerwood</surname><given-names>JE</given-names></string-name>, <string-name><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name><surname>Beigel</surname><given-names>JH</given-names></string-name></person-group>, <collab>mRNA-1273 Study Group</collab>. <year>2020</year>. <article-title>An mRNA vaccine against SARS-CoV-2—preliminary report</article-title>. <source>N Engl J Med</source><volume>383</volume>:<fpage>1920</fpage>–<lpage>1931</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id>.<pub-id pub-id-type="pmid">32663912</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anderson</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Rouphael</surname><given-names>NG</given-names></string-name>, <string-name><surname>Widge</surname><given-names>AT</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>PC</given-names></string-name>, <string-name><surname>Makhene</surname><given-names>M</given-names></string-name>, <string-name><surname>Chappell</surname><given-names>JD</given-names></string-name>, <string-name><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Pruijssers</surname><given-names>AJ</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>AB</given-names></string-name>, <string-name><surname>Flach</surname><given-names>B</given-names></string-name>, <string-name><surname>Lin</surname><given-names>BC</given-names></string-name>, <string-name><surname>Doria-Rose</surname><given-names>NA</given-names></string-name>, <string-name><surname>O'Dell</surname><given-names>S</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>SD</given-names></string-name>, <string-name><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>PA</given-names>, <suffix>II</suffix></string-name>, <string-name><surname>Padilla</surname><given-names>M</given-names></string-name>, <string-name><surname>Neuzil</surname><given-names>KM</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>H</given-names></string-name>, <string-name><surname>Leav</surname><given-names>B</given-names></string-name>, <string-name><surname>Makowski</surname><given-names>M</given-names></string-name>, <string-name><surname>Albert</surname><given-names>J</given-names></string-name>, <string-name><surname>Cross</surname><given-names>K</given-names></string-name>, <string-name><surname>Edara</surname><given-names>VV</given-names></string-name>, <string-name><surname>Floyd</surname><given-names>K</given-names></string-name>, <string-name><surname>Suthar</surname><given-names>MS</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>DR</given-names></string-name>, <string-name><surname>Baric</surname><given-names>R</given-names></string-name>, <string-name><surname>Buchanan</surname><given-names>W</given-names></string-name>, <string-name><surname>Luke</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Phadke</surname><given-names>VK</given-names></string-name>, <string-name><surname>Rostad</surname><given-names>CA</given-names></string-name>, <string-name><surname>Ledgerwood</surname><given-names>JE</given-names></string-name>, <string-name><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name><surname>Beigel</surname><given-names>JH</given-names></string-name></person-group>, <collab>mRNA-1273 Study Group</collab>. <year>2020</year>. <article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title>. <source>N Engl J Med</source><volume>383</volume>:<fpage>2427</fpage>–<lpage>2438</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2028436</pub-id>.<pub-id pub-id-type="pmid">32991794</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baden</surname><given-names>LR</given-names></string-name>, <string-name><surname>El Sahly</surname><given-names>HM</given-names></string-name>, <string-name><surname>Essink</surname><given-names>B</given-names></string-name>, <string-name><surname>Kotloff</surname><given-names>K</given-names></string-name>, <string-name><surname>Frey</surname><given-names>S</given-names></string-name>, <string-name><surname>Novak</surname><given-names>R</given-names></string-name>, <string-name><surname>Diemert</surname><given-names>D</given-names></string-name>, <string-name><surname>Spector</surname><given-names>SA</given-names></string-name>, <string-name><surname>Rouphael</surname><given-names>N</given-names></string-name>, <string-name><surname>Creech</surname><given-names>CB</given-names></string-name>, <string-name><surname>McGettigan</surname><given-names>J</given-names></string-name>, <string-name><surname>Khetan</surname><given-names>S</given-names></string-name>, <string-name><surname>Segall</surname><given-names>N</given-names></string-name>, <string-name><surname>Solis</surname><given-names>J</given-names></string-name>, <string-name><surname>Brosz</surname><given-names>A</given-names></string-name>, <string-name><surname>Fierro</surname><given-names>C</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>H</given-names></string-name>, <string-name><surname>Neuzil</surname><given-names>K</given-names></string-name>, <string-name><surname>Corey</surname><given-names>L</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>P</given-names></string-name>, <string-name><surname>Janes</surname><given-names>H</given-names></string-name>, <string-name><surname>Follmann</surname><given-names>D</given-names></string-name>, <string-name><surname>Marovich</surname><given-names>M</given-names></string-name>, <string-name><surname>Mascola</surname><given-names>J</given-names></string-name>, <string-name><surname>Polakowski</surname><given-names>L</given-names></string-name>, <string-name><surname>Ledgerwood</surname><given-names>J</given-names></string-name>, <string-name><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>H</given-names></string-name>, <string-name><surname>Pajon</surname><given-names>R</given-names></string-name>, <string-name><surname>Knightly</surname><given-names>C</given-names></string-name>, <string-name><surname>Leav</surname><given-names>B</given-names></string-name>, <string-name><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name><surname>Han</surname><given-names>S</given-names></string-name>, <string-name><surname>Ivarsson</surname><given-names>M</given-names></string-name>, <string-name><surname>Miller</surname><given-names>J</given-names></string-name>, <string-name><surname>Zaks</surname><given-names>T</given-names></string-name></person-group>, <collab>COVE Study Group</collab>. <year>2021</year>. <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>403</fpage>–<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id>.<pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Werner</surname><given-names>AP</given-names></string-name>, <string-name><surname>Koch</surname><given-names>M</given-names></string-name>, <string-name><surname>Choi</surname><given-names>A</given-names></string-name>, <string-name><surname>Narayanan</surname><given-names>E</given-names></string-name>, <string-name><surname>Stewart-Jones</surname><given-names>GBE</given-names></string-name>, <string-name><surname>Colpitts</surname><given-names>T</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>H</given-names></string-name>, <string-name><surname>Boyoglu-Barnum</surname><given-names>S</given-names></string-name>, <string-name><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name><surname>Moliva</surname><given-names>JI</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name><surname>Carfi</surname><given-names>A</given-names></string-name>, <string-name><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name><surname>Seder</surname><given-names>RA</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>DK</given-names></string-name></person-group>. <year>2021</year>. <article-title>Serum neutralizing activity elicited by mRNA-1273 vaccine</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>1468</fpage>–<lpage>1470</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2102179</pub-id>.<pub-id pub-id-type="pmid">33730471</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noori</surname><given-names>M</given-names></string-name>, <string-name><surname>Nejadghaderi</surname><given-names>SA</given-names></string-name>, <string-name><surname>Arshi</surname><given-names>S</given-names></string-name>, <string-name><surname>Carson-Chahhoud</surname><given-names>K</given-names></string-name>, <string-name><surname>Ansarin</surname><given-names>K</given-names></string-name>, <string-name><surname>Kolahi</surname><given-names>AA</given-names></string-name>, <string-name><surname>Safiri</surname><given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: a systematic review of in vitro studies</article-title>. <source>Rev Med Virol</source><pub-id pub-id-type="doi">10.1002/rmv.2277</pub-id>.</mixed-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name><surname>Nason</surname><given-names>MC</given-names></string-name>, <string-name><surname>Flach</surname><given-names>B</given-names></string-name>, <string-name><surname>Gagne</surname><given-names>M</given-names></string-name>, <string-name><surname>S</surname><given-names>OC</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>TS</given-names></string-name>, <string-name><surname>Shah</surname><given-names>SN</given-names></string-name>, <string-name><surname>Edara</surname><given-names>VV</given-names></string-name>, <string-name><surname>Floyd</surname><given-names>K</given-names></string-name>, <string-name><surname>Lai</surname><given-names>L</given-names></string-name>, <string-name><surname>McDanal</surname><given-names>C</given-names></string-name>, <string-name><surname>Francica</surname><given-names>JR</given-names></string-name>, <string-name><surname>Flynn</surname><given-names>B</given-names></string-name>, <string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Choi</surname><given-names>A</given-names></string-name>, <string-name><surname>Koch</surname><given-names>M</given-names></string-name>, <string-name><surname>Abiona</surname><given-names>OM</given-names></string-name>, <string-name><surname>Werner</surname><given-names>AP</given-names></string-name>, <string-name><surname>Alvarado</surname><given-names>GS</given-names></string-name>, <string-name><surname>Andrew</surname><given-names>SF</given-names></string-name>, <string-name><surname>Donaldson</surname><given-names>MM</given-names></string-name>, <string-name><surname>Fintzi</surname><given-names>J</given-names></string-name>, <string-name><surname>Flebbe</surname><given-names>DR</given-names></string-name>, <string-name><surname>Lamb</surname><given-names>E</given-names></string-name>, <string-name><surname>Noe</surname><given-names>AT</given-names></string-name>, <string-name><surname>Nurmukhambetova</surname><given-names>ST</given-names></string-name>, <string-name><surname>Provost</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Cook</surname><given-names>A</given-names></string-name>, <string-name><surname>Dodson</surname><given-names>A</given-names></string-name>, <string-name><surname>Faudree</surname><given-names>A</given-names></string-name>, <string-name><surname>Greenhouse</surname><given-names>J</given-names></string-name>, <string-name><surname>Kar</surname><given-names>S</given-names></string-name>, <string-name><surname>Pessaint</surname><given-names>L</given-names></string-name>, <string-name><surname>Porto</surname><given-names>M</given-names></string-name>, <string-name><surname>Steingrebe</surname><given-names>K</given-names></string-name>, <string-name><surname>Valentin</surname><given-names>D</given-names></string-name>, <string-name><surname>Zouantcha</surname><given-names>S</given-names></string-name>, <string-name><surname>Bock</surname><given-names>KW</given-names></string-name>, <string-name><surname>Minai</surname><given-names>M</given-names></string-name>, <string-name><surname>Nagata</surname><given-names>BM</given-names></string-name>, <string-name><surname>Moliva</surname><given-names>JI</given-names></string-name>, <string-name><surname>van de Wetering</surname><given-names>R</given-names></string-name>, <string-name><surname>Boyoglu-Barnum</surname><given-names>S</given-names></string-name>, <string-name><surname>Leung</surname><given-names>K</given-names></string-name>, <string-name><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ES</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Todd</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>H</given-names></string-name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates</article-title>. <source>Science</source><volume>373</volume>:<elocation-id>eabj0299</elocation-id>. <pub-id pub-id-type="doi">10.1126/science.abj0299</pub-id>.<pub-id pub-id-type="pmid">34529476</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Fontes-Garfias</surname><given-names>CR</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Cai</surname><given-names>H</given-names></string-name>, <string-name><surname>Sarkar</surname><given-names>R</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>M</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>D</given-names></string-name>, <string-name><surname>Weaver</surname><given-names>SC</given-names></string-name>, <string-name><surname>Muik</surname><given-names>A</given-names></string-name>, <string-name><surname>Sahin</surname><given-names>U</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>KU</given-names></string-name>, <string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Dormitzer</surname><given-names>PR</given-names></string-name>, <string-name><surname>Shi</surname><given-names>PY</given-names></string-name></person-group>. <year>2021</year>. <article-title>Neutralizing activity of BNT162b2-elicited serum</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>1466</fpage>–<lpage>1468</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2102017</pub-id>.<pub-id pub-id-type="pmid">33684280</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name><surname>Zou</surname><given-names>J</given-names></string-name>, <string-name><surname>Weaver</surname><given-names>SC</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Cai</surname><given-names>H</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>M</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>D</given-names></string-name>, <string-name><surname>Muik</surname><given-names>A</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>KU</given-names></string-name>, <string-name><surname>Sahin</surname><given-names>U</given-names></string-name>, <string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Dormitzer</surname><given-names>PR</given-names></string-name>, <string-name><surname>Shi</surname><given-names>PY</given-names></string-name></person-group>. <year>2021</year>. <article-title>BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants</article-title>. <source>Nature</source><volume>596</volume>:<fpage>273</fpage>–<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03693-y</pub-id>.<pub-id pub-id-type="pmid">34111888</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Zou</surname><given-names>J</given-names></string-name>, <string-name><surname>Fontes-Garfias</surname><given-names>CR</given-names></string-name>, <string-name><surname>Weaver</surname><given-names>SC</given-names></string-name>, <string-name><surname>Swanson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Cai</surname><given-names>H</given-names></string-name>, <string-name><surname>Sarkar</surname><given-names>R</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>M</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>D</given-names></string-name>, <string-name><surname>Muik</surname><given-names>A</given-names></string-name>, <string-name><surname>Sahin</surname><given-names>U</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>KU</given-names></string-name>, <string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Dormitzer</surname><given-names>PR</given-names></string-name>, <string-name><surname>Shi</surname><given-names>PY</given-names></string-name></person-group>. <year>2021</year>. <article-title>BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants</article-title>. <source>N Engl J Med</source><volume>385</volume>:<fpage>472</fpage>–<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2106083</pub-id>.<pub-id pub-id-type="pmid">33979486</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whitt</surname><given-names>MA</given-names></string-name></person-group>. <year>2010</year>. <article-title>Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines</article-title>. <source>J Virol Methods</source><volume>169</volume>:<fpage>365</fpage>–<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2010.08.006</pub-id>.<pub-id pub-id-type="pmid">20709108</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>DK</given-names></string-name>, <string-name><surname>Leist</surname><given-names>SR</given-names></string-name>, <string-name><surname>Abiona</surname><given-names>OM</given-names></string-name>, <string-name><surname>Boyoglu-Barnum</surname><given-names>S</given-names></string-name>, <string-name><surname>Gillespie</surname><given-names>RA</given-names></string-name>, <string-name><surname>Himansu</surname><given-names>S</given-names></string-name>, <string-name><surname>Schafer</surname><given-names>A</given-names></string-name>, <string-name><surname>Ziwawo</surname><given-names>CT</given-names></string-name>, <string-name><surname>DiPiazza</surname><given-names>AT</given-names></string-name>, <string-name><surname>Dinnon</surname><given-names>KH</given-names></string-name>, <string-name><surname>Elbashir</surname><given-names>SM</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>CA</given-names></string-name>, <string-name><surname>Woods</surname><given-names>A</given-names></string-name>, <string-name><surname>Fritch</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>DR</given-names></string-name>, <string-name><surname>Bock</surname><given-names>KW</given-names></string-name>, <string-name><surname>Minai</surname><given-names>M</given-names></string-name>, <string-name><surname>Nagata</surname><given-names>BM</given-names></string-name>, <string-name><surname>Hutchinson</surname><given-names>GB</given-names></string-name>, <string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Henry</surname><given-names>C</given-names></string-name>, <string-name><surname>Bahl</surname><given-names>K</given-names></string-name>, <string-name><surname>Garcia-Dominguez</surname><given-names>D</given-names></string-name>, <string-name><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name><surname>Renzi</surname><given-names>I</given-names></string-name>, <string-name><surname>Kong</surname><given-names>WP</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>SD</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Phung</surname><given-names>E</given-names></string-name>, <string-name><surname>Chang</surname><given-names>LA</given-names></string-name>, <string-name><surname>Loomis</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Altaras</surname><given-names>NE</given-names></string-name>, <string-name><surname>Narayanan</surname><given-names>E</given-names></string-name>, <string-name><surname>Metkar</surname><given-names>M</given-names></string-name>, <string-name><surname>Presnyak</surname><given-names>V</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name><surname>Louder</surname><given-names>MK</given-names></string-name>, <string-name><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name><surname>Leung</surname><given-names>K</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ES</given-names></string-name>, <string-name><surname>West</surname><given-names>A</given-names></string-name>, <string-name><surname>Gully</surname><given-names>KL</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name><surname>Wrapp</surname><given-names>D</given-names></string-name>, <string-name><surname>Doria-Rose</surname><given-names>NA</given-names></string-name>, <string-name><surname>Stewart-Jones</surname><given-names>G</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>H</given-names></string-name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title>. <source>Nature</source><volume>586</volume>:<fpage>567</fpage>–<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2622-0</pub-id>.<pub-id pub-id-type="pmid">32756549</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
